IGI Logo

Below are Quote on Cadila Healthcare to sell medicine for black fungus by Mr. Yash Gupta Equity Research Associate, Angel Broking Ltd   

Zydus Cadila and TLC, a specialty pharmaceutical company in Taiwan, announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ in India. AmphoTLC™ is a critical drug to treat Mucormycosis or Black Fungus in India. Under the terms of the agreement, TLC will manufacture and supply AmphoTLC™ on a non-exclusive basis to Zydus, and Zydus will commercialize AmphoTLC™ in India. The Central Drugs Standard Control Organization (CDSCO) of India has approved the New Drug Application (NDA) of TLC for Amphotericin B Liposome for Injection 50mg or AmphoTLC™ for immediate importation as per approved usage and indication. Mucormycosis is a serious fungal infection also known as black fungus, and COVID Associated Mucormycosis is a life-threatening form of mucormycosis which has emerged as a post-COVID complication, infecting about 30% of COVID patients who are diabetic or otherwise immune compromised. If progression of the infection is not treated early, over 60% of patients could die. The increasing number of CAM cases has resulted in unprecedented demand for liposomal amphotericin B, the key drug to treat mucormycosis, causing an acute shortage of the drug.

 

This will be a very important launch from Cadila Healthcare in the time of need for treatment of Black Fungus, we have seen a rise in demand for the drugs which are involved in treatment of Black Fungus. Critical drugs for Mucormycosis are very high cost drugs and even some of the drug prices are more than ₹10000 per dose, so this is going to be a very important launch for the Company and we expect the company to launch this product in a couple of weeks. 

 

Above views are of the author and not of the website kindly read disclaimer